Sarcomas are a heterogeneous group of malignant tumors of mesenchymal origin that potentially affect any part of the human body. Although considered relatively rare, these tumors constitute almost 1 % of all malignancies in adults and 12 % in the pediatric population. Diagnostic imaging plays an important role in the management of bone and soft tissue sarcomas, and both PET and PET/CT have been shown to be powerful noninvasive imaging methods with detection rates up to 95 %. Also for assessment of the local extent and staging metabolic imaging is useful. In addition, response to chemotherapy can be predicted noninvasive. Therefore, FDG PET has been included in guidelines (e.g., NCCN or ESMO). However, metabolic imaging of sarcomas is not generally accepted and often not reimbursed. Also the role of non-FDG tracers in clinical routine remains unclear in sarcoma. Because of the rarity of the tumor entity, multicenter trials are warranted to develop specific and profound recommendations for the use of FDG PET or non-FDG tracers in sarcoma. The initial promising results of stand-alone PET/MRI need also to be confirmed in larger patient cohorts.
- Bone sarcoma
- Soft tissue sarcoma
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging